Skip to main content
Fig. 5 | Experimental Hematology & Oncology

Fig. 5

From: Construction of CD19 targeted dual- and enhanced dual-antibodies and their efficiency in the treatment of B cell malignancy

Fig. 5

DuAb and EDuAb induce the activation of T cells derived from ALL patients and mediate the killing of their own ALL cells a Quantification and statistical analysis of CD69+, CD25+ and CD107a+ cells in T cells derived from ALL patients after co-cultured with their own ALL cells in the presence of DuAb or EDuAb. b Quantification of cytokines (IL-2, TNF-α, and IFN-γ) released into culture supernatants by patient derived T cells as results of activation and killing their own ALL cells mediated by DuAb or EDuAb. c Primary ALL cells were incubated with the ALL-derived T cells (E:T ratio of 5:1) for 72 h at 1 nM concentration of DuAb or EDuAb. Representative flow cytometry analysis of residual CD10+ tumor cells and remaining CD5+ T cells (Left panel). Tumor lysis was calculated based on residual CD10+ tumor cells (Right panel). (n = 4)

Back to article page